| The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010 | 4502 | 2010 |
| Integrative Clinical Genomics of Advanced Prostate Cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3963 | 2015 |
| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2814 | 2015 |
| Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer CE Barbieri, SC Baca, MS Lawrence, F Demichelis, M Blattner, ... Nature Genetics 44 (6), 685-689, 2012 | 1790 | 2012 |
| Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer H Beltran, D Prandi, JM Mosquera, M Benelli, L Puca, J Cyrta, C Marotz, ... Nature medicine, 2016 | 1611 | 2016 |
| Punctuated Evolution of Prostate Cancer Genomes SC Baca, D Prandi, MS Lawrence, JM Mosquera, A Romanel, Y Drier, ... Cell 153 (3), 666-677, 2013 | 1482 | 2013 |
| The genomic complexity of primary human prostate cancer MF Berger, MS Lawrence, F Demichelis, Y Drier, K Cibulskis, ... Nature 470 (7333), 214-220, 2011 | 1470 | 2011 |
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma R Beroukhim, G Getz, L Nghiemphu, J Barretina, T Hsueh, D Linhart, ... Proceedings of the National Academy of Sciences 104 (50), 20007-20012, 2007 | 1259 | 2007 |
| Genomic correlates of clinical outcome in advanced prostate cancer W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ... Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019 | 1200 | 2019 |
| Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets H Beltran, DS Rickman, K Park, SS Chae, A Sboner, TY MacDonald, ... Cancer Discovery 1 (6), 487-495, 2011 | 1016 | 2011 |
| SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ... Science 355 (6320), 84-88, 2017 | 999 | 2017 |
| Personalized in vitro and in vivo cancer models to guide precision medicine C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi, A Sboner, V Sailer, ... Cancer Discovery 7 (5), 462-477, 2017 | 956 | 2017 |
| TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort F Demichelis, K Fall, S Perner, O Andrén, F Schmidt, SR Setlur, ... Oncogene 26 (31), 4596-4599, 2007 | 845 | 2007 |
| The long tail of oncogenic drivers in prostate cancer J Armenia, SAM Wankowicz, D Liu, J Gao, R Kundra, E Reznik, ... Nature genetics 50 (5), 645-651, 2018 | 829 | 2018 |
| Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ... Journal of Clinical Oncology 36 (24), 2492, 2018 | 708 | 2018 |
| TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer S Perner, F Demichelis, R Beroukhim, FH Schmidt, JM Mosquera, S Setlur, ... Cancer research 66 (17), 8337-8341, 2006 | 680 | 2006 |
| TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion S Perner, JM Mosquera, F Demichelis, MD Hofer, PL Paris, J Simko, ... The American journal of surgical pathology 31 (6), 882-888, 2007 | 579 | 2007 |
| N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer E Dardenne, H Beltran, M Benelli, K Gayvert, A Berger, L Puca, J Cyrta, ... Cancer Cell 30 (4), 563-577, 2016 | 564 | 2016 |
| Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma N Palanisamy, B Ateeq, S Kalyana-Sundaram, D Pflueger, ... Nature medicine 16 (7), 793-798, 2010 | 561 | 2010 |
| Role of non-coding sequence variants in cancer E Khurana, Y Fu, D Chakravarty, F Demichelis, MA Rubin, M Gerstein Nature Reviews Genetics 17 (2), 93-108, 2016 | 551 | 2016 |
Mark A RubinProfessor & Director Department for BioMedical Research, University of BernEmail verificata su dbmr.unibe.ch
